C5A - Advancing Automation Tools to Accelerate Drug Development: Cross-SIG Perspectives

Co-Chair(s)

• 

  Jiawei Zhou, PhD (she/her/hers)

  Assistant Professor
  UNC-Chapel Hill, North Carolina, United States
• JS

  Jing Su, NA

  Executive Director, Statistical Programming
  Merck & Co., Inc.

Speaker(s)

• 

  Yuchen Wang, PhD

  Associate Director (PMx)
  Pfizer
• 

  Neelima Thanneer

  Executive Director
  Bristol Myers Squibb
• 

  Kenta Yoshida, PhD (he/him/his)

  Distinguished Scientist
  Clinical Pharmacology
  Genentech, Inc.

Panelist(s)

• EG

  Emma Xizhe Gao, PhD

  Clinical pharmacologist
  Pfizer Inc, United States
• CP

  Cesar Pichardo, PhD

  Senior Director, Systems Medicine
  AstraZeneca, United Kingdom
• 

  Matthew Fidler, M.Stat., PhD (he/him/his)

  Director
  Novartis
  Fort Worth, Texas, United States
• 

  Xiaobin Li, M.S

  Programming Director, CPMS Programming and Business Excellence
  GSK, North Carolina, United States

In the fast-paced drug development industry, time is both money and life. Automation tools that leverage computational workflows and artificial intelligence/machine learning (AI/ML) have become essential in streamlining processes and accelerating development timelines. This symposium will explore automation tools designed for pharmacometrics data visualization and review, exposure-response modeling and reporting, as well as automated tumor growth inhibition modeling and survival analysis simulation. Through these presentations, attendees will gain insights into cutting-edge automation tools that are revolutionizing pharmacometrics analyses, streamlining the entire workflow from data processing to modeling and reporting. By adopting these innovations, the industry can enhance efficiency, improve data-driven decision-making, and expedite drug development.
This symposium highlights cutting-edge automation tool development from the perspective of ISoP Special Interest Groups (SIGs). ISoP SIGs play a critical role in advancing model-informed drug development, working as voluntary committees to drive innovation and enhance drug development processes. While each SIG brings unique perspectives and expertise, we share a common goal: improving drug development and patient outcomes. In this cross-SIG session, we showcase our collaborative efforts in developing and utilizing automation tools to accelerate drug development while discussing future needs and challenges in automation tool development.

Presentations:

• 1:45 PM - 2:05 PM MDT

  Automation tools for pharmacometrics (PMX) dataset creation, review, and reporting
  

  Speaker: Neelima Thanneer – Bristol Myers Squibb
• 2:05 PM - 2:25 PM MDT

  PoissonERM: An example of an automation tool
  

  Speaker: Yuchen Wang, PhD – Pfizer
• 2:25 PM - 2:45 PM MDT

  Workstream for conducting a tumor growth inhibition-overall survival (TGI-OS) analysis and automation tool to streamline survival simulation
  

  Speaker: Kenta Yoshida, PhD (he/him/his) – Genentech, Inc.
• 2:45 PM - 3:15 PM MDT

  Panel - Advancing Automation Tools to Accelerate Drug Development: Cross-SIG Perspectives
  

  Panelist: Xiaobin Li, M.S – GSK

  Panelist: Yuchen Wang, PhD – Pfizer

  Panelist: Kenta Yoshida, PhD (he/him/his) – Genentech, Inc.

  Panelist: Emma Xizhe Gao, PhD – Pfizer Inc

  Panelist: Cesar Pichardo, PhD – AstraZeneca

  Panelist: Matthew L. Fidler, M.Stat., PhD (he/him/his) – Novartis

  Panelist: Limei Cheng, PhD – Incyte Corportation

  Panelist: Neelima Thanneer – Bristol Myers Squibb